Profile data is unavailable for this security.
About the company
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology, non-oncology prescription formulation, and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is marketing its products globally in approximately 150 countries. Its subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltd, and others.
- Revenue in INR (TTM)331.82bn
- Net income in INR34.87bn
- Incorporated1986
- Employees9.11k
- LocationAurobindo Pharma LtdWater Mark Building,, Plot No. 11Survey no.9, Kondapur, Hitech CityHyderabad,TelanganaHYDERABAD 500032IndiaIND
- Phone+91 4 066725000
- Fax+91 4 023741080
- Websitehttps://www.aurobindo.com/
More ▼
Mergers & acquisitions
| Acquired company | AUROPHARMA:NSI since announced | Transaction value |
|---|---|---|
| Khandelwal Laboratories Pvt Ltd-Business | 3.75% | 36.17m |
Data delayed at least 15 minutes, as of Mar 06 2026 10:29 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anthem BioSciences Ltd | 19.97bn | 4.85bn | 372.53bn | 2.06k | 77.21 | -- | 61.11 | 18.66 | 8.59 | 8.59 | 35.40 | -- | -- | -- | -- | 9,682,764.00 | -- | -- | -- | -- | 61.25 | -- | 24.27 | -- | -- | -- | -- | -- | 29.96 | -- | 22.86 | -- | -- | -- |
| Ajanta Pharma Ltd | 52.02bn | 10.15bn | 373.81bn | 9.63k | 36.84 | -- | 31.62 | 7.19 | 81.21 | 81.21 | 416.34 | -- | -- | -- | -- | 5,402,607.00 | -- | 17.31 | -- | 21.48 | 77.65 | 73.83 | 19.50 | 19.60 | -- | 96.70 | -- | 33.78 | 10.44 | 12.43 | 12.77 | 14.50 | 5.84 | 26.43 |
| IPCA Laboratories Ltd | 95.05bn | 9.10bn | 379.08bn | 18.04k | 41.66 | -- | 27.90 | 3.99 | 35.86 | 35.86 | 374.66 | -- | -- | -- | -- | 5,267,716.00 | -- | 9.16 | -- | 12.39 | 70.13 | 60.24 | 9.97 | 11.25 | -- | 19.58 | -- | 13.42 | 16.02 | 13.97 | 34.77 | 4.00 | 20.42 | 9.86 |
| GlaxoSmithKline Pharmaceuticals Ltd | 38.01bn | 10.21bn | 426.45bn | 3.11k | 41.77 | -- | 39.16 | 11.22 | 60.26 | 60.26 | 224.34 | -- | -- | -- | -- | 12,209,250.00 | -- | 15.30 | -- | 25.66 | 64.24 | 56.70 | 26.86 | 16.77 | -- | 452.52 | -- | 144.35 | 8.56 | 3.06 | 57.23 | 53.14 | -31.03 | 16.00 |
| Laurus Labs Ltd | 67.22bn | 8.43bn | 554.00bn | 6.17k | 65.74 | -- | 42.28 | 8.24 | 15.61 | 15.61 | 124.44 | -- | -- | -- | -- | 10,899,350.00 | -- | 8.88 | -- | 14.31 | 58.67 | 48.18 | 12.52 | 11.88 | -- | 7.10 | -- | 13.79 | 10.18 | 14.42 | 123.18 | 7.02 | 23.60 | -- |
| Abbott India Ltd | 68.24bn | 15.24bn | 580.64bn | 3.66k | 38.10 | -- | 36.31 | 8.51 | 717.26 | 717.26 | 3,211.47 | -- | -- | -- | -- | 18,650,260.00 | -- | 22.42 | -- | 30.42 | 46.61 | 44.59 | 22.33 | 18.83 | -- | 79.05 | -- | 73.99 | 9.58 | 9.38 | 17.75 | 18.99 | 27.31 | 34.73 |
| Glenmark Pharmaceuticals Ltd | 164.68bn | 10.65bn | 599.51bn | 13.48k | 56.31 | -- | 37.10 | 3.64 | 37.72 | 37.72 | 583.32 | -- | -- | -- | -- | 12,219,440.00 | -- | 1.33 | -- | 1.92 | 71.68 | 60.15 | 6.47 | 1.82 | -- | 16.41 | -- | 39.62 | 12.77 | 4.60 | 155.14 | 6.18 | -4.24 | 0.00 |
| Alkem Laboratories Ltd | 142.53bn | 23.71bn | 661.19bn | 18.64k | 27.88 | -- | 23.52 | 4.64 | 198.32 | 198.32 | 1,192.01 | -- | -- | -- | -- | 7,645,478.00 | -- | 12.12 | -- | 17.53 | 64.05 | 60.06 | 17.00 | 14.69 | -- | 18.13 | -- | 28.96 | 2.34 | 9.21 | 20.59 | 13.95 | 13.22 | 12.47 |
| Aurobindo Pharma Ltd | 331.82bn | 34.87bn | 715.49bn | 9.11k | 20.52 | -- | 13.68 | 2.16 | 60.04 | 60.04 | 571.33 | -- | -- | -- | -- | 36,435,560.00 | -- | 8.62 | -- | 12.13 | 59.35 | 53.55 | 10.50 | 12.38 | -- | 14.24 | -- | 7.25 | 9.39 | 6.55 | 9.86 | 4.15 | 11.98 | -- |
| Mankind Pharma Ltd | 138.42bn | 17.75bn | 902.80bn | 27.00k | 50.93 | -- | 33.72 | 6.52 | 42.95 | 43.05 | 334.94 | -- | -- | -- | -- | 5,126,748.00 | -- | 14.93 | -- | 19.39 | 71.39 | 67.59 | 13.00 | 17.70 | -- | 3.64 | -- | 0.00 | 18.98 | 15.79 | 3.90 | 14.03 | 18.41 | -- |
| Zydus Lifesciences Ltd | 260.89bn | 49.38bn | 918.74bn | 27.92k | 18.60 | -- | 15.13 | 3.52 | 49.08 | 49.08 | 259.31 | -- | -- | -- | -- | 9,345,309.00 | -- | 10.92 | -- | 16.35 | 73.12 | 63.12 | 18.91 | 16.73 | -- | -- | -- | 17.81 | 18.90 | 10.27 | 17.96 | 30.92 | 13.63 | 25.74 |
| Cipla Ltd | 283.51bn | 45.46bn | 1.07tn | 30.31k | 23.48 | -- | 19.17 | 3.76 | 56.26 | 56.26 | 350.81 | -- | -- | -- | -- | 9,352,779.00 | -- | 11.89 | -- | 14.49 | 66.53 | 59.55 | 16.03 | 14.74 | -- | 96.40 | -- | 22.40 | 6.88 | 9.97 | 27.93 | 27.80 | 9.14 | 34.08 |
| Lupin Ltd | 261.51bn | 46.45bn | 1.07tn | 19.98k | 21.58 | -- | 17.88 | 4.10 | 108.62 | 108.62 | 603.92 | -- | -- | -- | -- | 13,088,990.00 | -- | 4.53 | -- | 7.16 | 72.62 | 59.70 | 17.86 | 5.95 | -- | 183.80 | -- | 29.13 | 13.48 | 8.11 | 71.41 | -- | 20.11 | 14.87 |
Data as of Mar 06 2026. Currency figures normalised to Aurobindo Pharma Ltd's reporting currency: Indian Rupee INR
21.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 30 Jan 2026 | 26.37m | 4.54% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 18.67m | 3.22% |
| ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026 | 16.58m | 2.86% |
| Life Insurance Corporation of India (Investment Portfolio)as of 12 Sep 2024 | 13.16m | 2.27% |
| The Vanguard Group, Inc.as of 04 Feb 2026 | 10.87m | 1.87% |
| SBI Funds Management Ltd.as of 31 Jan 2026 | 10.63m | 1.83% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Jan 2026 | 9.27m | 1.60% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Jan 2026 | 6.96m | 1.20% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 6.44m | 1.11% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 5.87m | 1.01% |
More ▼
Data from 31 Dec 2025 - 15 Feb 2026Source: FactSet Research Systems Inc.
